OncoSec Medical Inc Stock OTC Bulletin Board
Equities
ONCS
US68234L1089
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2023 | Motion for Asset Sale Approved for OncoSec Medical Incorporated | CI |
2023 | Motion for Asset Sale Filed by OncoSec Medical Incorporated | CI |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 28.35M |
---|---|---|---|---|---|
Net income 2021 | -45M | Net income 2022 | -34M | EV / Sales 2021 | - |
Net cash position 2021 | 33.63M | Net cash position 2022 | 1.12M | EV / Sales 2022 | - |
P/E ratio 2021 |
-1.59
x | P/E ratio 2022 |
-0.83
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 84.57% |
Managers | Title | Age | Since |
---|---|---|---|
David Canton
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Sandra Aung
PRN | Corporate Officer/Principal | - | 20-10-11 |
Bridget O'Keeffe
PRN | Corporate Officer/Principal | - | 21-02-17 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+46.45% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- ONCSQ Stock
- ONCS Stock